Pharmacokinetics of oxfendazole nanosuspension in sheep

The pharmacokinetics of our previous prepared oxfendazole nanosuspension was studied in sheep to understand its enhancement of bioavailability. Ten sheep were randomly divided into two groups, each of which received a single-dose (5mg/kg) oral oxfendazole nanosuspension and oxfendazole granules. After intragastric administration, oxfendazole rapidly reached peak concentrations of 11.25 mu g/mL and 5.50 mu g/mL at 5.6 h and 6.6 h in the nanosuspension group and granules group and the concentrations gradually reduced to below the detection limit at 96 h and 72h, respectively. The main pharmacokinetic parameters of oxfendazole after administration to the sheep: The T-max, C-max, AUC(last), MRTlast, T-1/2 and Ke of in nanosuspension were 5.6 h, 11.26 mu g/mL, 179.22 mu g*h/mL, 17.82 h, 87.22 h and 0.012 1/h, respectively, while the these main pharmacokinetic parameters in the OFZ granules group were 6.6 h, 5.50 mu g/mL, 105.28 mu g*h/mL, 16.55 h, 3 5.04 h, and 0.020 1/h, respectively. Compared with the granules group, the C-max and AUC(last) of the nanosuspension group were increased by 2.05 and 1.70 times, respectively, and the C(max )and AUC(last) of the total active compound in the nanosuspension group w ere increased by 1.85 times and 1.71 times, respectively. These results suggest that the oxfendazole suspension might be an effective and promising formulation for use in sheep.